替换
查找内容:
替换为:
全部替换
插入链接
链接网址:
链接显示标题:
请选择网址类型
点我插入链接
插入文件
文件名称:
文件显示标题:
请选择文件类型
点我插入文件
发现错误 发表观点

原文内容

反馈意见

提交 正在提交..... 反馈历史

复制下面的地址分享给好友

确定 正在提交.....
train

你好,

关闭
提交 重做 重新开始 关闭
跳转
  • 新建同级
  • 新建子级
  • 删除
  • 重命名
选择收藏夹
新建收藏夹
公开

取消 确定

1. 基本信息
姓名:
企业:
职位:
联系方式:
邮箱:
2. 请在此填写您的问题,我们将优先安排答疑
提交

报名成功!
课程观看链接如下:
请添加课程助理微信,获得更多信息:
确认
确定
取消 确认

识林

  • 知识
  • 视频
  • 社区
  • 政策法规
    • 国内药监
    • FDA
    • EU
    • PIC/S
    • WHO
    • ICH
    • MHRA
    • PMDA
    • TGA
  • 研发注册
    • 概览
    • 监管动态
    • 研究专题
  • 生产质量
    • 概览
    • 监管动态
    • 各国GMP
    • 中国GMP
    • 中国GMP指南
    • GMP对比
    • 检查缺陷
    • 研究专题
  • 主题词库
  • 帮助中心
  • 关于识林
    • 识林介绍
    • 识林FAQs
    • 功能介绍
    • 团队诊断
    • 联系我们
  • 30天免登录

    忘记密码?

FDA发布罕见疾病Sanfilippo综合征的指导草案

首页 > 资讯 > FDA发布罕见疾病Sanfilippo综合征的指导草案

页面比对

出自识林

FDA发布罕见疾病Sanfilippo综合征的指导草案
Sanfilippo
原文地址
页面比对
笔记

2020-02-04 FDA

跳转到: 导航, 搜索

FDA Releases Guidance for Rare Disease Known as Sanfilippo Syndrome

The following quote is attributed to Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research:

“The FDA is committed to fostering innovation in drug development, especially for rare diseases. Patients who are suffering with rare diseases frequently have few or no treatments available to treat their condition and new approvals can often mean hope for an enhanced quality of life and in some cases, survival."

“As part of our commitment to innovation and to patients, we are issuing a draft guidance regarding the rare disease, Mucopolysaccharidosis Type III, also known as Sanfilippo Syndrome."

“There are no approved therapies to treat this disease and we hope that this guidance will foster greater efficiency and consistency among drug development programs, and ultimately benefit patients. ”

  • Today, the FDA issued the draft guidance, “Mucopolysaccharidosis Type III (Sanfilippo Syndrome): Developing Drugs for Treatment,” which provides recommendations to industry on important clinical trial design features that can support a robust clinical development program for the development of therapies for Mucopolysaccharidosis Type III (MPS III), also known as Sanfilippo Syndrome.
  • MPS III is a rare and life-threatening disorder, often appearing in children, in which the body is missing or does not have enough enzymes to break down long chains of sugar molecules, called glycosaminoglycans (GAG). The buildup of GAGs can lead to cellular damage and progressive tissue and organ dysfunction, primarily involving the central nervous system. The rate of progression of the neurological symptoms are not well characterized in MPS III.
  • Children with MPS III at birth appear healthy. The first symptoms are often mild developmental delays such as speech delays and usually appear between the ages of 2 and 6 years. As the disease progresses, children typically develop behavioral problems and gradual loss of developmental and cognitive skills. It may take years for children to receive a diagnosis for MPS III due to the rarity of the disease and the nonspecific initial symptoms.

Related Information

  • MedlinePlus: Mucopolysaccharidosis type III

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

【来源】
FDA Releases Guidance for Rare Disease Known as Sanfilippo Syndrome

【相关页面】
Mucopolysaccharidosis Type III (Sanfilippo Syndrome): Developing Drugs for Treatment

取自“https://login.shilinx.com/wiki/index.php?title=FDA%E5%8F%91%E5%B8%83%E7%BD%95%E8%A7%81%E7%96%BE%E7%97%85Sanfilippo%E7%BB%BC%E5%90%88%E5%BE%81%E7%9A%84%E6%8C%87%E5%AF%BC%E8%8D%89%E6%A1%88”
上一页: FDA发布首个2019年新型冠状病毒诊断的紧急使用授权
下一页: FDA_关于新型冠状病毒爆发的血液机构的重要信息
相关内容
相关新闻
  • FDA批准Givosiran治疗急性肝卟...
  • FDA批准首例治疗遗传性罕见病...
  • FDA继续开展罕见病治疗的重要...
  • 制药行业热捧罕见病用药,FDA...
  • 美国和欧盟提议罕见儿科疾病多...
热点新闻
  • ICH 发布新 Q1 稳定性指南...
  • 【直播】25年4月全球法规月报...
  • 【识林新工具】AI知识助手,AI...
  • 【识林新文章】中国无菌附录对...
  • VHP(过氧化氢蒸汽)的“脆弱...

 反馈意见

Copyright ©2011-2025 shilinx.com All Rights Reserved.
识林网站版权所有 京ICP备12018650号-2 (京)网药械信息备字(2022)第00078号
请登录APP查看
打开APP